Brief: TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies
04/01/2022 12:09
Jan 4 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS AND ARBOR BIOTECHNOLOGIES ESTABLISH
COLLABORATION TO ADVANCE ALLOGENEIC TRUC-T CELL THERAPIES
* TCR2 THERAPEUTICS - UNDER TERMS OF AGREEMENT, ARBOR WILL
RECEIVE
AN UPFRONT CASH PAYMENT AND IS ALSO ELIGIBLE TO RECEIVE
ADDITIONAL MILESTONE PAYMENTS
Source text for Eikon: ID:nGNX2kLfpd
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview